Predicting liver cancer riskNonalcoholic fatty liver disease (NAFLD) raises the risk of developing hepatocellular carcinoma (HCC), but this risk can be difficult to quantify and disease onset can still be difficult to catch early. Fujiwara et al. developed hepatic transcriptome and serum secretome–derived signatures to predict NAFLD-related HCC in patients over 15 years of observation.… Continue reading Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease
Tag: NAFLD
Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study
The aim of this study was to determine the impact at 5 years of sodium-glucose cotransporter 2 inhibitor (SGLT2i) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM) on liver histopathology and clinical features. In this retrospective study, the histological impacts at 5 years after the start of SGLT2i in NAFLD with T2DM were… Continue reading Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study
Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
BackgroundGiven the association of NAFLD with metabolic risks, a name change to MAFLD is proposed. We compared the long-term outcomes of NAFLD and MAFLD. MethodsWe included patients with fatty liver disease (FLD) from NHANES III and NHANES 2017–2018 (FLD defined as moderate to severe hepatic steatosis by ultrasound for NHANES III and as having a… Continue reading Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
526.3 – Liver Proteomic Profile in Mice on a High-Fat Diet: Modulation with Anti-Tumor Intervention
Presenting AuthorUniversity of Michigan ntroduction: Nonalcoholic fatty liver disease (NAFLD) is becoming a primary cause of liver damage in Western society. Nonalcoholic steatohepatitis (NASH) is an advanced stage of NAFLD and may lead to liver cancer. Our previous long-term murine studies have shown the beneficial role of Aquamin, a red marine algae-derived (calcium, magnesium, additional… Continue reading 526.3 – Liver Proteomic Profile in Mice on a High-Fat Diet: Modulation with Anti-Tumor Intervention
Inverse association between serum 25-hydroxyvitamin D and nonalcoholic fatty liver disease
AbstractBackground & AimsSerum 25-hydroxyvitamin D (S-25(OH)D) and nonalcoholic fatty liver disease (NAFLD) are correlated in many observational studies, whereas the causality of this association is uncertain, especially in European populations. We conducted a bidirectional Mendelian randomization study to determine the association between S-25(OH)D and NAFLD. MethodsSeven and six independent genetic variants associated with S-25(OH)D and… Continue reading Inverse association between serum 25-hydroxyvitamin D and nonalcoholic fatty liver disease
Food Insecurity is Associated with Mortality Among U.S. Adults with Nonalcoholic Fatty Liver Disease and Advanced Fibrosis
Food insecurity is a growing public health challenge in the U.S. and has been linked to nonalcoholic fatty liver disease (NAFLD) and advanced fibrosis. However, little is known of how food insecurity impacts mortality risk and healthcare utilization (HCU) in chronic liver disease. MethodsUsing a population-based cohort study of U.S. adults (≥20 years) in the… Continue reading Food Insecurity is Associated with Mortality Among U.S. Adults with Nonalcoholic Fatty Liver Disease and Advanced Fibrosis
ADAMTSL2 protein and a soluble biomarker signature identify significant and advanced #fibrosis in adults with #NAFLD
Using an aptamer-based profiling platform we identified an individual and panel of circulating proteins that non-invasively identify significant fibrosis at-risk NASH in 316 adults with NAFLD.•An 8-protein panel can distinguish NAFL/NASH fibrosis stage 0-1 from fibrosis stage 2-4 with an AUROC 0.87- 0.89.•The ADAMTSL2 protein alone can distinguish NAFL/NASH fibrosis stage 0-1 from fibrosis stage… Continue reading ADAMTSL2 protein and a soluble biomarker signature identify significant and advanced #fibrosis in adults with #NAFLD
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic #fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
AMP kinase (AMPK) is an energy sensor implicated in regulation of lipid metabolism, inflammation, and insulin sensitivity. We aimed to assess efficacy and safety of PXL770, a novel direct AMPK activator, in patients with non-alcoholic fatty liver disease (NAFLD). MethodsSTAMP-NAFLD, a randomised, double-blind, placebo-controlled phase 2a study, was done across 15 US clinical sites. Patients… Continue reading Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic #fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study
A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary #Heart Disease in Non-alcoholic #Fatty Liver Disease
Background and AimsCardiovascular disease remains the leading cause of death in patients with non-alcoholic fatty liver disease (NAFLD). Studies examining the association of coronary heart disease (CHD) and NAFLD are cofounded by various cardiometabolic factors particularly diabetes and body mass index. Hence, we seek to explore such association by investigating the global prevalence, independent risk… Continue reading A Meta-Analysis on the Global Prevalence, Risk factors and Screening of Coronary #Heart Disease in Non-alcoholic #Fatty Liver Disease
2 Medical News 